General Information of Drug (ID: DM1R5X4)

Drug Name
Becaplermin Drug Info
Synonyms Regranex; Regranex (TN); Becaplermin (USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1]
Therapeutic Class
Antiulcer Agents
Cross-matching ID
TTD Drug ID
DM1R5X4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [3]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [4]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [5]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [8]
SNN-0031 DM2X3BR Brain injury NA07.Z Phase 1/2 [9]
TAK-593 DMNFZOT Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [11]
PMID25656651-Compound-21a DMCKAON N. A. N. A. Patented [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Modulator [2]

References

1 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
4 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
5 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
6 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
7 National Cancer Institute Drug Dictionary (drug id 452042).
8 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
9 Company report (Neuronova)
10 Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
11 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
12 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.